- Verified Reactivity
- Human, Cynomolgus, Rhesus
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- PHA activated human lymphocytes
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
- Preparation
- The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
SB - Reported in the literature, not verified in house
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
- Excitation Laser
- Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
- Application Notes
The A1 antibody binds to the human CD39 cell surface antigen and has been shown to block MHC independent target cell recognition by hapten-specific CTL. Additional reported applications (for the relevant formats) include: in vitro CD39 blockade3,? immunofluorescence4,?immunohistochemistry6, and spatial biology (IBEX)7,8. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for blocking assays (contact our custom solutions team).
- Additional Product Notes
Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
- Application References
(PubMed link indicates BioLegend citation) -
- Aversa GG, et al. 1988. Transplant. P. 20:4952.
- Aversa GG, et al. 1989. Transplant. P. 21:34950.
- Borsellino G, et al. 2007. Blood. 110:1225. (Block)
- Stockl J, et al. 2001. J. Immunol. 167:2724. (IF)
- Sestak K, et al. 2007. Vet. Immunol. Immunopathol. 119:21.
- Lyck L, et al. 2008. J. Histochem. Cytochem. 56:201. (IHC)
- Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
- Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed
- Product Citations
-
- Boer M, et al. 2015. Clin Vaccine Immunol. 22: 778 - 788. PubMed
- Man L, et al. 2020. Cell Reports. 32(6):108027. PubMed
- Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
- Carnevale J, et al. 2022. Nature. 609:174. PubMed
- Pagel J, et al. 2020. Front Immunol. 11:565257. PubMed
- Wu L, et al. 2018. Oncol Lett. 15:9507. PubMed
- Wang J, et al. 2019. Oncol Lett. 4.948611111. PubMed
- Leng T, et al. 2019. Cell Rep. 28:3077. PubMed
- Panigrahi S, et al. 2020. Eur J Immunol. 50:2055. PubMed
- RRID
- AB_940427 (BioLegend Cat. No. 328207) AB_940429 (BioLegend Cat. No. 328208)